A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Immunogenicity of the ExPEC4V (JNJ-63871860) Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Subjects Aged 18 Years and Older
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs JNJ 63871860 (Primary)
- Indications Escherichia coli infections; Urinary tract infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Research & Development
- 19 Jun 2019 Status changed from active, no longer recruiting to completed.
- 11 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2018 Status changed from not yet recruiting to recruiting.